X

Jubilant Pharmova Q4FY23 Earnings Story

The three business components of Jubilant Pharmova Ltd, which include medicines, contract research and development services, and patented new therapies, make up this integrated global pharmaceuticals corporation.

Financial Results:

  • Jubilant Pharmova Ltd. reported Total Income for Q4FY23 of ₹ 1,683 Crores up from ₹ 1,525 Crore year on year, a rise of 10%.

  • Total Expenses for Q4FY23 of ₹ 1,786 Crores up from ₹ 1,420 Crores year on year, rise of 26%.

  • Consolidated Net Profit of ₹ (101) Crores, down from ₹ 591 Crores in the same quarter of the previous year.

  • The Earnings per Share is ₹ (6.15), down from ₹ 3.74 in the same quarter of the previous year.
Related Post